IN
Valneva SE
INRLF · OTC
$3.16 -2.47% (-$0.08)
1M -3.95%
Market Cap 522.1M €
P/E Ratio -
Div. Yield -
ROE 152.16%
Bulios Fair Price
$2.76
12.7% downside
Current Price
$3.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INRLF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
34 /100
Fair P/B 6.45x
P/S 3.65x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 21.54%
Rev. growth 21.52%
FCF growth N/A
Profitability
4 /100
Weak Op. margin 82.29%
Gross margin 16.40%
FCF margin 46.69%
Quality
5 /100
Poor ROA 40.68%
ROIC 38.52%
Asset turnover 0.37x
Debt
23 /100
High Int. coverage -2.95x
Debt/Equity 2.59x
Current ratio 2.16x
Stability
16 /100
Unstable EPS volatility 401.68%
Beta 1.35x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INRLF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas Lingelbach
Employees
674
Headquarters
Saint-Herblain
Upcoming events
12 NOV
Earnings
Upcoming earnings report